Investigational drug · Phase 2
Imzokitug
Also called: BMS-986340
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Imzokitug"
First trial start
2021
May 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Imzokitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Cervical Cancer
- Gastric/Gastroesophageal Junction Adenocarcinoma
- Microsatellite Stable Colorectal Cancer
- Non-Small-Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Renal Cell
- Urothelial Carcinoma
- Pancreatic Adenocarcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Imzokitug" as an intervention, largest first.
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07680764 · 160 participants (planned) · Start Sep 10, 2026 · Primary completion Sep 15, 2028
Drug: Pumitamig; Imzokitug and 4 more · For: Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sites: Washington D.C., District of Columbia; Athens, Georgia; Lexington, Kentucky · 74 sites in all
Mayo ClinicAcademic, hospital or other
NCT07226856 · 43 participants (planned) · Start Dec 12, 2025 · Primary completion Feb 28, 2027
Drug: Gemcitabine; Imzokitug and 2 more · For: Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.